Yale Cancer Center – Immunotherapy Combination Shows Promise in Early Stage Triple Negative Breast Cancer

Some breast cancers are found to be triple negative, meaning that they are tested negative for estrogen receptors (ER-), progesterone receptors (PR-), and HER2 (HER2-). “A Yale Cancer Center clinical trial combining the immune checkpoint inhibitor (durvalumab/MEDI4736) with chemotherapy as preoperative treatment for early stage triple negative breast cancer showed a 71% pathologic complete response […]

Read More Yale Cancer Center – Immunotherapy Combination Shows Promise in Early Stage Triple Negative Breast Cancer

Checkpoint Inhibitors Advancing in Multiple GI Cancers – Gastroenterology & Endoscopy News

Immunotherapy is already used in a variety of different cancers with great success , and clinical trials are ongoing to test different approaches. Checkpoint inhibitors, specifically agents targeting programmed death-1 (PD-1), are being studied in clinical trials in a number of gastrointestinal tumors, including dMMR/MSI-H tumors which are associated with upregulated expression of checkpoint regulators […]

Read More Checkpoint Inhibitors Advancing in Multiple GI Cancers – Gastroenterology & Endoscopy News